Pramipexole Aurovitas Spain 1.05 mg prolonged-release tablets EFG

Package leaflet: Information for the user

Introduction

Package leaflet: information for the user

Pramipexole Aurovitas Spain 1.05 mg prolonged-release tablets EFG

Read the entire leaflet carefully before you start taking this medicine, because it contains important information for you.

• Keep this leaflet as you may need to read it again.
• If you have any questions, ask your doctor or pharmacist.
• This medicine has been prescribed for you only, and you should not give it to other people, even if they have the same symptoms as you, because it may harm them.
• If you experience any adverse reactions, consult your doctor or pharmacist, even if they are adverse reactions not listed in this leaflet. See section 4.

Contents of this leaflet

1. What Pramipexole Aurovitas Spain is and what it is used for
2. What you need to know before taking Pramipexole Aurovitas Spain
3. How to take Pramipexole Aurovitas Spain
4. Possible side effects
5. How to store Pramipexole Aurovitas Spain
6. Contents of the pack and other information

1. What Pramipexole Aurovitas Spain is and what it is used for

Pramipexole contains the active substance pramipexole and belongs to a group of medicines called dopamine agonists, which stimulate dopamine receptors in the brain. Stimulation of dopaminergic receptors triggers nerve impulses in the brain that help control body movements.

Pramipexole Aurovitas Spain is used to:

• treat the symptoms of idiopathic Parkinson's disease in adults. It can be used alone or in combination with levodopa (another medicine for Parkinson's disease).

2. What you need to know before taking Pramipexole Aurovitas Spain

Do not take Pramipexole Aurovitas Spain

If you are allergic to pramipexole or to any of the other ingredients of this medicine (listed in section 6).

Warnings and precautions

Talk to your doctor or pharmacist before starting to take Pramipexole Aurovitas Spain. Inform your doctor if you have or have had any illness or symptoms, especially any of the following:

• Kidney disease.
• Hallucinations (seeing, hearing, or feeling things that are not present). Most hallucinations are visual.
• Dyskinesia (e.g., abnormal involuntary movements of the limbs). If you have advanced Parkinson's disease and are also taking levodopa, you may develop dyskinesia during the gradual dose increase of Pramipexole Aurovitas Spain.
• Dystonia (inability to keep the trunk and neck straight and upright [axial dystonia]). Specifically, you may experience forward bending of the head and neck (also known as antecollis), forward curvature of the lumbar spine (also known as camptocormia), or sideways curvature of the back (also known as pleurothotonus or Pisa syndrome).
• Drowsiness and sudden sleep episodes.
• Psychosis (e.g., symptoms similar to schizophrenia).
• Vision disturbances. You should undergo periodic eye examinations during treatment with Pramipexole Aurovitas Spain.
• Severe heart or blood vessel disease. You should have periodic blood pressure checks, especially at the beginning of treatment, to prevent orthostatic hypotension (a drop in blood pressure upon standing).

Inform your doctor if you, your family, or caregivers notice that you are developing urges or impulses to behave in ways that are unusual for you and that you cannot resist the urge, impulse, or temptation to carry out certain activities that could harm you or others. This is known as impulse control disorder and may include behaviors such as gambling addiction, excessive eating or spending, or abnormally increased sexual appetite or interest with an increase in sexual thoughts and feelings. Your doctor may need to adjust your dose or discontinue treatment.

Inform your doctor if you, your family, or caregivers notice that you are developing mania (agitation, feeling elated or overexcited) or delirium (reduced awareness, confusion, or loss of contact with reality). Your doctor may need to adjust your dose or discontinue treatment.

Inform your doctor if you experience symptoms such as depression, apathy, anxiety, fatigue, sweating, or pain when stopping or reducing treatment with pramipexole. If these problems persist for more than a few weeks, your doctor may need to adjust your treatment.

Inform your doctor if you notice an inability to keep your trunk and neck straight and upright (axial dystonia). In such cases, your doctor may decide to adjust or modify your treatment.

Pramipexole Aurovitas Spain prolonged-release tablets are specially designed tablets from which the active ingredient is gradually released after ingestion. Occasionally, parts of the tablets may be excreted and seen in the stools, which may resemble intact tablets. Inform your doctor if you find tablet fragments in your stools.

Children and adolescents

Pramipexole Aurovitas Spain is not recommended for use in children or adolescents under 18 years of age.

Other medicines and Pramipexole Aurovitas Spain

Inform your doctor or pharmacist if you are taking, have recently taken, or might need to take any other medicines. This includes herbal medicines, dietary supplements, or natural health products obtained without a prescription.

You should avoid using Pramipexole Aurovitas Spain together with antipsychotic medicines.

Use caution if you are taking the following medicines:

• cimetidine (used to treat excess stomach acid and ulcers);
• amantadine (which may be used in the treatment of Parkinson's disease);
• mexiletine (used to treat irregular heartbeats, a condition known as ventricular arrhythmia);
• zidovudine (which may be used to treat acquired immunodeficiency syndrome [AIDS], a disease of the human immune system);
• cisplatin (used to treat various types of cancer);
• quinine (which may be used to prevent painful leg cramps occurring at night and to treat a type of malaria known as falciparum malaria [malignant malaria]);
• procainamide (used to treat irregular heartbeat).

If you are taking levodopa, it is recommended to reduce the dose of levodopa when starting treatment with Pramipexole Aurovitas Spain.

Use caution if you are taking sedative medicines (with a sedative effect) or drinking alcohol. In these cases, Pramipexole Aurovitas Spain may affect your ability to drive or operate machinery.

Taking Pramipexole Aurovitas Spain with food, drinks, and alcohol

You should be cautious if you drink alcohol during treatment with Pramipexole Aurovitas Spain.

You may take Pramipexole Aurovitas Spain with or without food.

Pregnancy, breastfeeding, and fertility

If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medicine. Your doctor will advise you whether you should continue treatment with Pramipexole Aurovitas Spain.

The effect of pramipexole on the unborn baby is not known. Therefore, do not take Pramipexole Aurovitas Spain during pregnancy unless your doctor specifically instructs you to do so.

Pramipexole Aurovitas Spain should not be used during breastfeeding. Pramipexole may reduce the production of breast milk. In addition, it may pass into breast milk and reach your baby. If the use of Pramipexole Aurovitas Spain is essential, breastfeeding must be discontinued. Consult your doctor or pharmacist before using any medicine.

Driving and using machines

Pramipexole Aurovitas Spain may cause hallucinations (seeing, hearing, or feeling things that are not present). If this occurs, do not drive or operate machinery.

Pramipexole has been associated with drowsiness and sudden sleep episodes, especially in patients with Parkinson's disease. If you experience these side effects, you should not drive or operate machinery. Inform your doctor if this happens.

3. How to take Pramipexole Aurovitas Spain

Follow exactly the instructions given by your doctor for taking this medicine. If in doubt, consult your doctor again. Your doctor will tell you the correct dose.

Take Pramipexole Aurovitas Spain prolonged-release tablets once daily, at the same time each day.

You may take Pramipexole Aurovitas Spain with or without food. The tablets should be swallowed whole with water.

Do not chew, divide, or crush the prolonged-release tablets. Doing so may result in an overdose, as the medicine could be released into your body too quickly.

During the first week, the usual daily dose is 0.26 mg of pramipexole. This dose will be increased every 5–7 days according to your doctor's instructions until your symptoms are controlled (maintenance dose).

The usual maintenance dose is 1.05 mg daily. However, your dose may need to be increased further. If necessary, your doctor may increase your tablet dose up to a maximum of 3.15 mg of pramipexole per day. It may also be possible to reduce the maintenance dose to one prolonged-release tablet of Pramipexole Aurovitas Spain 0.26 mg daily.

Patients with renal disease

If you have kidney disease, your doctor may advise you to take the usual starting dose of 0.26 mg prolonged-release tablets every other day during the first week. Afterwards, your doctor may increase the frequency to one 0.26 mg prolonged-release tablet daily. If further dose increases are needed, your doctor may adjust your dose in increments of 0.26 mg of pramipexole.

If you have severe kidney disease, your doctor may consider it necessary to switch you to a different pramipexole medication. If during treatment your kidney problems worsen, contact your doctor as soon as possible.

If you are switching from Pramipexole Aurovitas Spain immediate-release tablets

Your doctor will base your dose of Pramipexole Aurovitas Spain prolonged-release tablets on the dose of Pramipexole Aurovitas Spain immediate-release tablets you were taking.

On the day before the switch, take your pramipexole immediate-release tablets as you normally do. On the following morning, take your pramipexole prolonged-release tablet and do not take any further pramipexole immediate-release tablets.

If you take more Pramipexole Aurovitas Spain than you should

If you accidentally take too many tablets:

• contact your doctor or the nearest hospital emergency department immediately.
• you may experience vomiting, restlessness, or any of the adverse effects described in section 4, “Possible side effects”.

In case of overdose or accidental ingestion, contact your doctor or pharmacist immediately or call the Toxicology Information Service at telephone number 91 562 04 20, indicating the medication and the amount ingested.

If you forget to take Pramipexole Aurovitas Spain

If you forget to take your dose of pramipexole but remember within 12 hours of your usual time, take your tablet and continue with the next tablet at your usual time.

If you remember more than 12 hours after your usual time, simply take the next dose at your usual time. Do not take a double dose to make up for a missed dose.

If you stop taking Pramipexole Aurovitas Spain

Do not stop your treatment with Pramipexole Aurovitas Spain without first consulting your doctor. If you need to stop treatment with this medicine, your doctor will gradually reduce your dose. This reduces the risk of worsening symptoms.

If you have Parkinson's disease, you must not stop treatment with Pramipexole Aurovitas Spain abruptly. Sudden discontinuation may cause a condition called neuroleptic malignant syndrome, which may pose a serious health risk. These symptoms include:

• akinesia (loss of muscular movement)
• muscle rigidity
• fever
• unstable blood pressure
• tachycardia (increased heart rate)
• confusion
• decreased level of consciousness (e.g. coma).

If you stop treatment or reduce the dose of Pramipexole Aurovitas Spain, you may also experience a medical condition known as dopamine agonist withdrawal syndrome.

Symptoms include depression, apathy, anxiety, fatigue, sweating, or pain. If you experience these symptoms, you should contact your doctor.

If you have any further questions about the use of this medicine, ask your doctor or pharmacist.

4. Possible adverse effects

Like all medicines, this medicine may cause adverse effects, although not everybody will experience them. The classification of adverse effects is based on the following frequencies:

You may experience the following adverse effects:

Very common:

• Dyskinesia (e.g. abnormal involuntary movements of the limbs)
• Somnolence
• Dizziness
• Nausea

Common:

• Urge to behave in an unusual way
• Hallucinations (seeing, hearing, or feeling things that are not present)
• Confusion
• Fatigue
• Insomnia
• Fluid retention, usually in the legs (peripheral edema)
• Headache
• Hypotension (low blood pressure)
• Abnormal dreams
• Constipation
• Visual disturbances
• Vomiting (feeling sick)
• Weight loss including loss of appetite

Uncommon:

• Paranoia (e.g. excessive concern about your health)

• Delusion

• Excessive daytime sleepiness and sudden sleep attacks

• Amnesia (memory impairment)

• Hyperkinesia (increased movements and inability to stay still)

• Weight gain

• Allergic reactions (e.g. skin rash, itching, hypersensitivity)

• Fainting

• Heart failure (heart problems that may cause shortness of breath or ankle swelling)*

• Inappropriate secretion of antidiuretic hormone*

• Restlessness

• Dyspnea (difficulty breathing)

• Hiccups

• Pneumonia (lung infection)

• Inability to resist the impulse, urge, or temptation to perform an action that may be harmful to yourself or others, which may include:

• Strong urge to gamble excessively despite serious personal or family consequences

• Altered or increased sexual interest and behavior that is concerning to you or others, e.g. increased libido

• Compulsive shopping or spending

• Binge eating (consuming large amounts of food in a short period of time) or compulsive eating (eating more food than normal and more than needed to satisfy hunger)*

• Delirium (reduced awareness, confusion, loss of contact with reality)

Rare:

• Mania (agitation, feeling elated or overexcited)
• Spontaneous penile erection

Frequency not known:

• After stopping or reducing treatment with pramipexole: depression, apathy, anxiety, fatigue, sweating, or pain (known as dopamine agonist withdrawal syndrome or DAWS) may occur.

Inform your doctor if you experience any of these behaviors; he or she will explain how to manage or reduce the symptoms.

For adverse effects marked with *, an accurate estimation of frequency is not possible, as these adverse effects were not observed in clinical trials involving 2,762 patients treated with pramipexole. The frequency category is likely no higher than "uncommon."

Reporting of adverse effects

If you experience any adverse effect, consult your doctor or pharmacist, even if it is a possible adverse effect not listed in this leaflet. You can also report them directly via the Spanish Pharmacovigilance System for Human Medicines: https://www.notificaram.es. By reporting adverse effects, you can help provide more information on the safety of this medicine.

5. Storage of Pramipexole Aurovitas Spain

Keep this medicine out of sight and reach of children.

Do not use this medicine after the expiry date stated on the packaging after "EXP". The expiry date is the last day of the month indicated.

No special storage conditions are required.

Medicines must not be disposed of via wastewater or household waste. Dispose of unused medicines and their containers at a SIGRE point at your pharmacy. If you are unsure, ask your pharmacist how to dispose of medicines and containers you no longer need. This will help protect the environment.

6. Contents of the pack and other information

Composition of Pramipexol Aurovitas Spain

The active substance is pramipexole. Each tablet contains 0.26 mg of pramipexole as 0.375 mg of pramipexole dihydrochloride monohydrate.

The other components are: hypromellose, calcium phosphate dibasic, magnesium stearate and colloidal anhydrous silica.

Appearance of the product and contents of the container

Pramipexol Aurovitas Spain 0.26 mg prolonged-release tablets are white or almost white, cylindrical, flat and bevelled tablets, marked with "026" on one side. Each pack contains 30 tablets.

Marketing Authorization Holder

Aurovitas Spain, S.A.U.

Avda. de Burgos, 16-D

28036 Madrid

Spain

Manufacturer

LABORATORIOS NORMON, S.A.

Ronda de Valdecarrizo, 6 – 28760 Tres Cantos – Madrid (SPAIN)

OTHER PRESENTATIONS

Pramipexol Aurovitas Spain 1.05 mg prolonged-release tablets EFG.

Pramipexol Aurovitas Spain 2.1 mg prolonged-release tablets EFG.

Date of the most recent review of this summary: February 2025

Detailed and up-to-date information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/